Menlo Park, California, January 5, 2012. 3-V Biosciences, Inc. announced today both the closing of a Preferred Stock financing and the designation of a novel program targeting a host-factor for the treatment of Hepatitis C virus (HCV). “The continued support of the company’s investors for the host-factor vision reflects both the success of the team thus far and the potential for this program to play an import role improving the lives of patients with HCV,” said Merdad V. Parsey, MD, PhD, …
read more3-V Biosciences Closes Preferred Stock Financing and Designates Novel Host-Factor Hepatitis C Program
Comments Off
January 5, 2012
3-V Biosciences Appoints George W.Kemble, PhD, as Chief Scientific Officer
Comments Off
August 15, 2011
Menlo Park, California, August 15, 2011. 3-V Biosciences, Inc. announced today the appointment of George W. Kemble, PhD as Chief Scientific Officer. “We are very pleased to have George as the newest member of the 3-V senior management team,” said Merdad V. Parsey, MD, PhD, 3-V’s Chief Executive Officer. “George’s extensive experience in drug discovery and development, as well as virology and host cell biology, brings additional strength to the 3-V team and will further our efforts in this novel …
read more3-V Biosciences Promotes Stephen R.Brady to Chief Business Officer
Comments Off
February 10, 2011
Menlo Park, California, February 10, 2011. 3-V Biosciences, Inc. announced today Stephen R. Brady has been named as Chief Business Officer. “Steve’s contributions have been pivotal as a member of the team during his tenure at 3-V,” said Merdad V. Parsey, MD, PhD, 3-V’s Chief Executive Officer. “I look forward to working with him as we continue to build the 3-V team and advance the company’s programs.” Mr. Brady joined the 3-V team in 2010 as Vice President, Corporate Development, …
read more3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer
Comments Off
September 30, 2010
Menlo Park, California, September 30, 2010. 3-V Biosciences, Inc. announced today the appointment of Merdad V. Parsey, MD, PhD as Chief Executive Officer. We are very pleased to have Merdad as the new CEO of 3-V,” said David M. Mott, 3-V’s Executive Chairman, who is returning to his role as Chairman of the Board. “Merdad’s extensive drug development experiences in different therapeutic areas, including infectious disease, coupled with his experience in respiratory medicine, make him an excellent choice to lead …
read moreJames F. Young joins 3-V Biosciences Board of Directors
Comments Off
July 20, 2010
Menlo Park, California, July 20, 2010. 3-V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its Board of Directors. “We are very pleased to welcome Jim Young to the 3-V Board,” said David M. Mott, 3-V’s Executive Chairman. “Jim’s expertise as a virologist, immunologist, drug developer and company builder make him extraordinarily well suited to assist 3-V in its mission to build the leading host cell factor anti-infective company. Jim has a great nose for science …
read more3-V Biosciences Appoints Edward M. Connor, Jr., MD, Chief Medical Officer
Comments Off
June 3, 2010
Menlo Park, California, June 3, 2010. 3-V Biosciences, Inc. announced today the appointment of Edward M. Connor, Jr., MD, as Chief Medical Officer. “Ed Connor is among the most experienced respiratory infectious disease drug developers in the world, having led the development of RespiGam and Synagis® for respiratory syncytial virus and FluMist® for influenza,” said David M. Mott, 3-V’s Executive Chairman. “He has further extensive experience in infectious disease, immunology and oncology from his role as Executive Vice President and …
read more3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations
Comments Off
May 13, 2010
Menlo Park, California, May 13, 2010. 3-V Biosciences, Inc. announced today the appointment of Stephen R. Brady to the post of Vice President, Corporate Development, Strategy & Operations, the consolidation of all preclinical research under Robert S. McDowell, Ph.D. as Vice President, Research, and the integration of the company into new office and lab space in Menlo Park, California. We are very pleased to welcome Steve Brady to the 3-V team, and to expand Bob McDowell’s responsibilities within the organization, “ said David …
read more